ADMA BIOLOGICS, INC. Business Acquisition, Pro Forma Revenue
ADMA BIOLOGICS, INC. (ADMA) reported Business Acquisition, Pro Forma Revenue of $124.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-08-05
- ADMA BIOLOGICS, INC. business acquisition, pro forma revenue for the quarter ending 2026-06-30 was $124.39M, a 1.98% increase year-over-year.
- ADMA BIOLOGICS, INC. business acquisition, pro forma revenue for the quarter ending 2026-03-31 was $114.49M, a 0.27% decline year-over-year.
- ADMA BIOLOGICS, INC. business acquisition, pro forma revenue for the quarter ending 2025-06-30 was $121.98M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma revenue for the quarter ending 2025-03-31 was $114.80M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma revenue for fiscal 2017 was $41.02M, a 52.69% decline from fiscal 2016.
- ADMA BIOLOGICS, INC. business acquisition, pro forma revenue for fiscal 2016 was $86.71M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $124.39M 10-Q · filed 2026-08-05 | $238.89M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $114.49M 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $121.98M 10-Q · filed 2026-08-05 | $236.79M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $114.80M 10-Q · filed 2026-05-06 | |||
| 2017-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $16.73M derived: sum of 2 quarters · filed 2019-03-13 | $27.30M derived: sum of 3 quarters · filed 2019-03-13 | $41.02M 10-K · filed 2019-03-13 |
| 2017-09-30 | $4.73M 10-Q · filed 2018-11-09 | $15.30M derived: sum of 2 quarters · filed 2018-11-09 | $29.02M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $10.57M 10-Q · filed 2018-08-10 | $24.29M 10-Q · filed 2018-08-10 | ||
| 2016-12-31 | $23.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $42.83M derived: sum of 2 quarters · filed 2018-03-29 | $65.53M derived: sum of 3 quarters · filed 2018-03-29 | $86.71M 10-K · filed 2018-03-29 |
| 2016-09-30 | $19.61M 10-Q · filed 2017-11-03 | $42.31M derived: sum of 2 quarters · filed 2017-11-03 | $63.48M 10-Q · filed 2017-11-03 | |
| 2016-06-30 | $22.70M 10-Q · filed 2017-08-11 | $44.34M 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |